Search Results - "Melissa, O'Gorman"

Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study by Chen, Joseph, O’Gorman, Melissa T., James, Lee P., Klamerus, Karen J., Mugundu, Ganesh, Pithavala, Yazdi K.

“…Background Lorlatinib demonstrated efficacy (including intracranial activity) in patients with anaplastic lymphoma kinase ( ALK )-positive non-small cell lung…”
Get full text

Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function by Yu, Yanke, Hoffman, Justin, Plotka, Anna, O’Gorman, Melissa, Shi, Haihong, Wang, Diane

“…Purpose This publication describes an evaluation of the impact of different degrees of renal impairment on the pharmacokinetics and safety of palbociclib after…”
Get full text

Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants by Hibma, Jennifer E., O’Gorman, Melissa, Nepal, Sunil, Pawlak, Sylvester, Ginman, Katherine, Pithavala, Yazdi K.

“…Purpose Lorlatinib is a third-generation tyrosine kinase inhibitor currently approved for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic…”
Get full text

The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants by Patel, Maulik, Chen, Joseph, McGrory, Stephanie, O’Gorman, Melissa, Nepal, Sunil, Ginman, Katherine, Pithavala, Yazdi K.

“…Summary Background The third-generation tyrosine kinase inhibitor lorlatinib is approved for the treatment of ALK-positive metastatic NSCLC. CYP3A plays a…”
Get full text

Evaluation of the effect of ritlecitinib on the pharmacokinetics of caffeine in healthy participants by Liu, Jian, Solan, Rohit, Wolk, Robert, Plotka, Anna, O'Gorman, Melissa T., Winton, Jennifer A., Kaplan, Julia, Purohit, Vivek S.

“…Aims This clinical study was conducted to evaluate the impact of ritlecitinib on the pharmacokinetics of caffeine, a cytochrome P450 1A2 (CYP1A2) substrate…”
Get full text

Effect of food on the bioavailability of palbociclib by Ruiz-Garcia, Ana, Plotka, Anna, O’Gorman, Melissa, Wang, Diane D.

“…Purpose This phase I study estimated the effect of food on bioavailability of palbociclib (IBRANCE ® ), and a selective inhibitor of cyclin-dependent kinase…”
Get full text

Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals by Wang, Xiaoxing, Dowty, Martin E., Wouters, Ann, Tatulych, Svitlana, Connell, Carol A., Le, Vu H., Tripathy, Sakambari, O’Gorman, Melissa T., Winton, Jennifer A., Yin, Natalie, Valdez, Hernan, Malhotra, Bimal K.

“…Background and Objective Abrocitinib is a Janus kinase 1-selective inhibitor for the treatment of moderate-to-severe atopic dermatitis. Abrocitinib is…”
Get full text

The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects by Xu, Huiping, O’Gorman, Melissa, Tan, Weiwei, Brega, Nicoletta, Bello, Akintunde

“…Purpose To investigate the potential effects of strong CYP3A inhibitor ketoconazole and strong CYP3A inducer rifampin on the pharmacokinetics of crizotinib in…”
Get full text

Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals by Wang, Xiaoxing, Dowty, Martin E., Tripathy, Sakambari, Le, Vu H., Huh, Yeamin, Curto, Madelyn, Winton, Jennifer A., O’Gorman, Melissa T., Chan, Gary, Malhotra, Bimal K.

“…Background and Objective Abrocitinib is an oral small-molecule Janus kinase (JAK)-1 inhibitor approved for the treatment of moderate-to-severe atopic…”
Get full text

Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants by Hibma, Jennifer E., O’Gorman, Melissa, Nepal, Sunil, Pawlak, Sylvester, Ginman, Katherine, Pithavala, Yazdi K.

Get full text

Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects by Xu, Huiping, O'Gorman, Melissa, Boutros, Tanya, Brega, Nicoletta, Kantaridis, Constantino, Tan, Weiwei, Bello, Akintunde

“…Crizotinib (Xalkori®) is an orally administered, selective, small‐molecule, ATP‐competitive inhibitor of the anaplastic lymphoma kinase (ALK) and mesenchymal…”
Get full text

Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer by Chen, Joseph, Bearz, Alessandra, Kim, Dong-Wan, Mamdani, Hirva, Bauman, Jessica, Chiari, Rita, Ou, Sai-Hong Ignatius, Solomon, Benjamin J., Soo, Ross A., Felip, Enriqueta, Shaw, Alice T., Thurm, Holger, Clancy, Jill S., Lee, Kimberly, O’Gorman, Melissa, Tanski, Cherie, Pithavala, Yazdi K.

“…Background and Objective Lorlatinib is a tyrosine kinase inhibitor approved for the treatment of advanced anaplastic lymphoma kinase–positive non-small cell…”
Get full text

Evaluation of the Impact of Ritlecitinib on Organic Cation Transporters Using Sumatriptan and Biomarkers as Probes by Wang, Xiaoxing, Purohit, Vivek, Dowty, Martin E., Rodrigues, David, Luo, Lina, Mathialagan, Sumathy, Carey, William, Plotka, Anna, Kalluru, Hindu, Melissa, O'Gorman, Kaplan, Julia, Huh, Yeamin, Vourvahis, Manoli, Wolk, Robert M.

“…ABSTRACT Ritlecitinib, an inhibitor of Janus kinase 3 and hepatocellular carcinoma family kinases, is in development as potential treatment for several…”
Get full text

Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects by Johnson, Theodore R., Tan, Weiwei, Goulet, Lance, Smith, Evan B., Yamazaki, Shinji, Walker, Gregory S., O'Gorman, Melissa T., Bedarida, Gabriella, Zou, Helen Y., Christensen, James G., Nguyen, Leslie N., Shen, Zhongzhou, Dalvie, Deepak, Bello, Akintunde, Smith, Bill J.

“…Abstract 1. Crizotinib (XALKORI®), an oral inhibitor of anaplastic lymphoma kinase (ALK) and mesenchymal-epithelial transition factor kinase (c-Met), is…”
Get full text

The Bioequivalence of Tafamidis 61‐mg Free Acid Capsules and Tafamidis Meglumine 4 × 20‐mg Capsules in Healthy Volunteers by Lockwood, Peter A., Le, Vu H., O'Gorman, Melissa T., Patterson, Terrell A., Sultan, Marla B., Tankisheva, Ekaterina, Wang, Qiang, Riley, Steve

“…Tafamidis, a non‐nonsteroidal anti‐inflammatory benzoxazole derivative, acts as a transthyretin (TTR) stabilizer to slow progression of TTR amyloidosis (ATTR)…”
Get full text

Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants by Xu, Huiping, O'Gorman, Melissa T., Nepal, Sunil, James, Lee P., Ginman, Katherine, Pithavala, Yazdi K.

“…Lorlatinib is approved worldwide as treatment for anaplastic lymphoma kinase‐positive and c‐ros oncogene 1‐positive non‐small cell lung cancer. The objectives…”
Get full text

Pharmacokinetics, Safety, and Tolerability Following Multiple Oral Doses of Varenicline Under Various Titration Schedules in Elderly Nonsmokers by Zhao, Qinying, Schwam, Elias, Fullerton, Terence, O'Gorman, Melissa, Burstein, Aaron H.

“…This study was designed to investigate the multiple‐dose pharmacokinetics, safety, and tolerability of the selective α4β2 nicotinic acetylcholine partial…”
Get full text

No Effect of a Single Supratherapeutic Dose of Lersivirine, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor, on Corrected QT Interval in Healthy Subjects by Vourvahis, Manoli, Wang, Rong, Ndongo, Marie-Noella, O'Gorman, Melissa, Tawadrous, Margaret

“…The objective of this study was to investigate the effect of a supratherapeutic dose of lersivirine (LRV) on corrected QT (QTc) interval using Fridericia's…”
Get full text

A Novel Series of Non-Carboxylic Acid, Non-Hydantoin Inhibitors of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models:  6-(5-Chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and Congeners by Mylari, Banavara L, Armento, Sandra J, Beebe, David A, Conn, Edward L, Coutcher, James B, Dina, Michael S, O'Gorman, Melissa T, Linhares, Michael C, Martin, William H, Oates, Peter J, Tess, David A, Withbroe, Gregory J, Zembrowski, William J

“…Discovery of a highly selective, potent, and safe non-carboxylic acid, non-hydantoin inhibitor of aldose reductase (AR) capable of potently blocking the excess…”
Get full text

Effects of Renal Function on Crizotinib Pharmacokinetics: Dose Recommendations for Patients with ALK-Positive Non-Small Cell Lung Cancer by Tan, Weiwei, Yamazaki, Shinji, Johnson, Theodore R., Wang, Rong, O’Gorman, Melissa T., Kirkovsky, Leonid, Boutros, Tanya, Brega, Nicoletta M., Bello, Akintunde

“…Background and Objectives Crizotinib (250 mg twice daily) is the first anaplastic lymphoma kinase (ALK) inhibitor approved for treatment of ALK -positive…”
Get full text